An insight into time-limited therapy in CLL

Considering the optimal treatment strategy for patients with genetically high-risk CLLПодробнее

Time-limited therapy in CLLПодробнее

Clinical trial updates and time-limited therapy in CLLПодробнее

MURANO Trial and Time-Limited TherapiesПодробнее

An insight into the future treatment landscape of CLLПодробнее

A retrospective study of outcomes with ven-based treatment in cBTKi-treated, chemotherapy-naïve CLLПодробнее

Selection for time-limited & continuous therapy in CLLПодробнее

Time-limited vs continuous therapy in CLL treatmentПодробнее

Optimizing initial therapy in CLL: time-limited, all-oral approachesПодробнее

Moving towards time-limited treatment in frontline CLLПодробнее

Insights into the future of the CLL treatment landscapeПодробнее

Dr. Davids on Cost Effectiveness of Time-Limited Therapy With Venetoclax/Obinutuzumab in CLLПодробнее

Understanding patient perspectives in CLL treatmentПодробнее

An insight into resistance mechanisms of CLL cells to CAR-T therapyПодробнее

Choosing between continuous and time-limited therapy in patients with high-risk CLLПодробнее

Targeted therapy in CLL in 2022 and in the futureПодробнее

Dr. Woyach on the Utility of Time-Limited Therapies in CLLПодробнее

Dr. Pagel on Time-Limited Therapy in CLLПодробнее

Insights into the TARMAC study: time-limited ibrutinib and tisa-cel in patients with R/R MCLПодробнее

Continuous BTKi therapy in CLL: are time-limited combination therapies more beneficial?Подробнее